Literature DB >> 19609975

Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression.

Stephanie K Watkins1, Bing Li, Katharine S Richardson, Kimberly Head, Nejat K Egilmez, Qun Zeng, Jill Suttles, Robert D Stout.   

Abstract

This study reveals that the IL-15 rapidly released into serum upon IL-12 injection into tumor-bearing mice is critical for the subsequent leukocytic infiltration of the tumor and tumor-bearing tissue. The increase in serum IL-15 occurs within 2 h after IL-12 injection concomitantly with a decrease in cytoplasmic IL-15 in tumor-associated Mphi (TAM). Injection of anti-IL-15 one hour prior to IL-12 abrogates subsequent leukocytic infiltration into the tumor and prevents the IL-12-induced reduction of primary tumor mass and the clearance of metastases. Administration of anti-IL-15 18 h after IL-12 did not have a detectable impact on IL-12-induced leukocytic infiltration of the tumor. Deletion of NK cells had no impact on the IL-12-induced change in the functional phenotype of TAM or on the subsequent initiation of leukocytic infiltration of the tumor. In concert with our previous studies demonstrating that IL-12 reduces tumor-supportive activities of TAM, the current study supports the hypothesis that functional re-programming of TAM not only undermines Mphi support for tumor growth but also contributes to a critical step in the initiation of anti-tumor immune responses. In this context, the functional plasticity and pro-immunogenic potential of TAM may constitute a significant and unappreciated target in existing cytokine therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609975      PMCID: PMC2841431          DOI: 10.1002/eji.200839010

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  53 in total

1.  IL-15-induced conversion of monocytes to mature dendritic cells.

Authors:  K U Saikh; A S Khan; T Kissner; R G Ulrich
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR.

Authors:  Michael W Pfaffl; Graham W Horgan; Leo Dempfle
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

3.  Tumor vaccination with cytokine-encapsulated microspheres.

Authors:  Nejat K Egilmez; Yong S Jong; Edith Mathiowitz; Richard B Bankert
Journal:  Methods Mol Med       Date:  2003

4.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Authors:  J M Wigginton; E Gruys; L Geiselhart; J Subleski; K L Komschlies; J W Park; T A Wiltrout; K Nagashima; T C Back; R H Wiltrout
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 5.  Interleukin-2 and interleukin-15: immunotherapy for cancer.

Authors:  Todd A Fehniger; Megan A Cooper; Michael A Caligiuri
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

6.  Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.

Authors:  Kangla Tsung; James P Dolan; Ying L Tsung; Jeffrey A Norton
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

Review 7.  Critical role for IL-15 in innate immunity.

Authors:  Toshiaki Ohteki
Journal:  Curr Mol Med       Date:  2002-06       Impact factor: 2.222

8.  Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma.

Authors:  Stephen D Hess; Nejat K Egilmez; Nicola Bailey; Timothy M Anderson; Edith Mathiowitz; Steven H Bernstein; Richard B Bankert
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

9.  Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.

Authors:  Hank C Hill; Thomas F Conway; Michael S Sabel; Yong S Jong; Edith Mathiowitz; Richard B Bankert; Nejat K Egilmez
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

10.  IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.

Authors:  Alberto Comes; Emma Di Carlo; Piero Musiani; Ombretta Rosso; Raffaella Meazza; Claudia Chiodoni; Mario P Colombo; Silvano Ferrini
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

View more
  13 in total

Review 1.  Exercise training and immune crosstalk in breast cancer microenvironment: exploring the paradigms of exercise-induced immune modulation and exercise-induced myokines.

Authors:  Jorming Goh; Negin Niksirat; Kristin L Campbell
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

3.  Pigment epithelium-derived factor (PEDF) promotes tumor cell death by inducing macrophage membrane tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Authors:  Tsung-Chuan Ho; Show-Li Chen; Shou-Chuan Shih; Shing-Jyh Chang; Su-Lin Yang; Jui-Wen Hsieh; Huey-Chuan Cheng; Lee-Jen Chen; Yeou-Ping Tsao
Journal:  J Biol Chem       Date:  2011-08-16       Impact factor: 5.157

Review 4.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

Review 5.  Anti-tumour strategies aiming to target tumour-associated macrophages.

Authors:  Xiaoqiang Tang; Chunfen Mo; Yongsheng Wang; Dandan Wei; Hengyi Xiao
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

6.  Global gene expression profiles of canine macrophages and canine mammary cancer cells grown as a co-culture in vitro.

Authors:  Magdalena Król; Karol M Pawłowski; Kinga Majchrzak; Małgorzata Gajewska; Alicja Majewska; Tomasz Motyl
Journal:  BMC Vet Res       Date:  2012-02-21       Impact factor: 2.741

Review 7.  Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.

Authors:  Marc Baay; Anja Brouwer; Patrick Pauwels; Marc Peeters; Filip Lardon
Journal:  Clin Dev Immunol       Date:  2011-11-17

Review 8.  Bacterial immunotherapy of gastrointestinal tumors.

Authors:  Michael Linnebacher; Claudia Maletzki; Ulrike Klier; Ernst Klar
Journal:  Langenbecks Arch Surg       Date:  2011-12-22       Impact factor: 3.445

9.  Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Authors:  Stefania Croci; Patrizia Nanni; Arianna Palladini; Giordano Nicoletti; Valentina Grosso; Giorgia Benegiamo; Lorena Landuzzi; Alessia Lamolinara; Marianna L Ianzano; Dario Ranieri; Massimiliano Dall'Ora; Manuela Iezzi; Carla De Giovanni; Pier-Luigi Lollini
Journal:  Breast Cancer Res       Date:  2015-05-22       Impact factor: 6.466

10.  CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma.

Authors:  Young Wha Koh; Chan-Sik Park; Dok Hyun Yoon; Cheolwon Suh; Jooryung Huh
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.